Making cancer care smart with Oncotype IQ genomic tests
Improve outcomes by optimizing cancer care treatment and monitoring
LEARN MORE
Vilma, an Oncotype DX patient
VIEW EVENTS

Join us at the Atlanta Precision Oncology Symposium

February 5th, 2022, 7:40–8:10 AM EST

Join Dr. Joshua Routh at APOS for a Sponsored Breakfast Symposium: Next-Generation Sequencing on Small Tumor Specimens and/or Low Tumor Content Samples Using Novel Platforms.

RxPONDER Data Published!

Read the press release to learn more about how the newly published RxPONDER data helps inform treatment for node positive patients.

Redesigned Clinically Low-Risk Report

Oncotype DX Genomic Prostate Score Assay

Introducing the newly re-designed Oncotype DX GPS assay report for clinically low-risk prostate cancer patients.

20-Year Outcomes: Adverse Pathology

Oncotype DX Genomic Prostate Score Assay

New follow-up data suggests adverse pathology as a predictor of prostate cancer specific mortality and metastasis for clinically low-risk prostate cancer patients for up to 20 years after diagnosis.
Improving Patient Outcomes

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™